HC Wainwright Lowers TCR2 Therapeutics (NASDAQ:TCRR) Price Target to $13.00

TCR2 Therapeutics (NASDAQ:TCRRGet Rating) had its price target lowered by HC Wainwright from $14.00 to $13.00 in a research note published on Monday morning, The Fly reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for TCR2 Therapeutics’ Q4 2022 earnings at ($0.82) EPS, FY2022 earnings at ($3.19) EPS, Q1 2023 earnings at ($0.84) EPS, Q2 2023 earnings at ($0.87) EPS, Q3 2023 earnings at ($0.89) EPS, Q4 2023 earnings at ($0.91) EPS and FY2023 earnings at ($3.51) EPS.

TCRR has been the topic of several other reports. Piper Sandler dropped their price objective on shares of TCR2 Therapeutics from $16.00 to $8.00 in a research report on Tuesday, November 8th. Truist Financial lowered their price target on shares of TCR2 Therapeutics to $18.00 in a research report on Tuesday, August 23rd. Finally, Roth Capital reaffirmed a buy rating on shares of TCR2 Therapeutics in a research report on Monday, August 8th.

TCR2 Therapeutics Price Performance

Shares of TCRR opened at $1.27 on Monday. The firm has a market capitalization of $49.10 million, a PE ratio of -0.41 and a beta of 1.77. The company’s 50-day moving average is $1.60 and its 200-day moving average is $2.41. TCR2 Therapeutics has a fifty-two week low of $1.23 and a fifty-two week high of $5.65.

Institutional Investors Weigh In On TCR2 Therapeutics

A number of large investors have recently bought and sold shares of TCRR. GSA Capital Partners LLP grew its stake in TCR2 Therapeutics by 113.2% during the first quarter. GSA Capital Partners LLP now owns 158,593 shares of the company’s stock worth $438,000 after buying an additional 84,191 shares in the last quarter. Private Advisor Group LLC boosted its stake in shares of TCR2 Therapeutics by 205.1% in the 1st quarter. Private Advisor Group LLC now owns 33,631 shares of the company’s stock valued at $93,000 after purchasing an additional 22,608 shares in the last quarter. Acadian Asset Management LLC boosted its stake in shares of TCR2 Therapeutics by 3,250.7% in the 1st quarter. Acadian Asset Management LLC now owns 479,518 shares of the company’s stock valued at $1,322,000 after purchasing an additional 465,207 shares in the last quarter. BlackRock Inc. boosted its stake in shares of TCR2 Therapeutics by 5.5% in the 1st quarter. BlackRock Inc. now owns 2,532,916 shares of the company’s stock valued at $6,991,000 after purchasing an additional 131,171 shares in the last quarter. Finally, Federated Hermes Inc. boosted its stake in shares of TCR2 Therapeutics by 166.7% in the 1st quarter. Federated Hermes Inc. now owns 15,707 shares of the company’s stock valued at $43,000 after purchasing an additional 9,818 shares in the last quarter. 64.56% of the stock is currently owned by institutional investors and hedge funds.

TCR2 Therapeutics Company Profile

(Get Rating)

TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

Featured Articles

The Fly logo

Receive News & Ratings for TCR2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TCR2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.